Nami Surgical has appointed Nikki Palfrey as CEO while completing its latest investment round. As it eyes the global robotic-assisted surgery market, the funding will help the company commercialize its ultrasonic technology.

Nami develops high-performance miniaturised ultrasonic scalpels; its platform has been engineered for integration into articulated, wristed surgical robotic instruments, addressing growing demand for compatibility with next-generation robotic systems. The robotic-assisted surgery market is forecast to reach more than $25 billion by 2030.

Palfrey, who has been a non-executive director at Nami since 2023, has more than 25 years of medtech leadership experience, guiding businesses such as Summit Medical and BOWA Medical UK through growth, transformation, and global expansion. As CEO, Palfrey will lead Nami’s commercial strategy and partner engagement as the company progresses towards market entry. Co-Founder Nico Fenu assumes the chief operating officer role; he started the University of Glasgow spinout with Chief Technology Officer Rebecca Cleary in 2021.

“Nami is well-positioned to become a leading force in the robotic-assisted surgery market,” Palfrey said. “Building on the strong foundations established by Nico, Rebecca, and the entire team, I am excited to lead the company as we enter an exciting new chapter focused on innovation, scale, and long-term value creation.”

Nami recently completed its latest investment, a £1.9 million round led by Eos Advisory with participation from the Investment Fund for Scotland managed by Maven Capital Partners (and delivered by the British Business Bank), and Scottish Enterprise.

“As founders, Rebecca and I are incredibly proud of how far Nami has come. We are excited about the opportunities ahead in a rapidly growing global market and remain deeply committed to our mission of improving patient outcomes worldwide,” Fenu stated.

Current U.S.-based adviser David O’Reilly has been named as Eos Advisory’s investor director and joins Nami’s board, which is chaired by Albert Nicholl. O’Reilly brings significant experience in scaling high-growth technology businesses and strengthens the company’s strategic and governance capabilities as Nami moves towards commercial execution.

“Nami’s miniaturized ultrasonic platform is exactly the kind of enabling breakthrough that can reshape the competitive landscape in robotic surgery and notably marks a gap in the portfolios of the major medical robotic companies in the space,” O’Reilly concluded.